en Radiation Biology Radiation Biology تحقيق بديع Original Research <div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:newspaper"><span style="text-kashida-space:50%"><span style="line-height:119%"><span style="font-family:Calibri"><span style="color:black"><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Background</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">This study aims to evaluate the clinical efficacy of concurrent chemoradiotherapy for nasopharyngeal carcinoma (NPC) following induction chemotherapy (IC) with albumin-bound paclitaxel (ABP) combined with carboplatin, through the analysis of serum biomarkers and dynamic contrast-enhanced magnetic resonance imaging (MRI) data. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Material and Methods: </span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">Ninety-six NPC patients were rolled into Group I (concurrent chemoradiotherapy) and Group II (IC with ABP and carboplatin+concurrent chemoradiotherapy). DCE-MRI scans were utilized to evaluate changes in lesion characteristics. Serum samples were collected to analyze tumor markers including cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), SCC-associated antigen (SCC-Ag), and carbohydrate antigen 125 (CA-125), as well as superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) activity, and malondialdehyde (MDA) levels. Toxicities and 2-year overall survival (OS) and progression-free survival (PFS) were also assessed. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Results: </span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">Group II exhibited a markedly higher objective response rate and disease control rate versus Group I (35.4% vs. 58.3%, 50.0% vs. 81.3%, respectively). MRI scans revealed a drastic reduction in the proportion of patients with obvious enhancement of primary lesions, invasion of the base of the skull/medial pterygoid muscle, etc. Serum levels of CYFRA21-1, SCC-Ag, CA125, and MDA were greatly decreased, while SOD and GSH-Px activities were notably increased (P<0.05). Group II showed a considerable increase in OS and PFS versus Group I (75.0% vs. 89.6%, 68.8% vs. 83.3%, respectively, P<0.05). </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Conclusion: </span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">the combination of ABP and carboplatin has demonstrated enhanced efficacy and improved survival outcomes in patients with NPC, providing new insights and evidence for clinical application.</span></span></span></span></span></span></span></span></span></div> Albumin-bound paclitaxel, carboplatin, nasopharyngeal carcinoma, dynamic contrast-enhanced MRI, serum biomarkers, clinical efficacy. 427 433 http://ijrr.com/browse.php?a_code=A-10-1-1346&slc_lang=en&sid=1 M. Huang jiqawrp975@163.com 7900319475328460031145 7900319475328460031145 Yes Department of Radiotherapy, Zhuji People's Hospital, Zhuji 311809, Zhejiang Province, China G. Wang 7900319475328460031146 7900319475328460031146 No Department of Radiotherapy, Zhuji People's Hospital, Zhuji 311809, Zhejiang Province, China F. Xuan 7900319475328460031147 7900319475328460031147 No Department of Radiotherapy, Zhuji People's Hospital, Zhuji 311809, Zhejiang Province, China